181 related articles for article (PubMed ID: 24682137)
1. Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.
Ngcozana T; Ong V; Denton CP
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24682137
[TBL] [Abstract][Full Text] [Related]
2. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
Hamaguchi Y; Sumida T; Kawaguchi Y; Ihn H; Tanaka S; Asano Y; Motegi SI; Kuwana M; Endo H; Takehara K
J Dermatol; 2017 Jan; 44(1):13-17. PubMed ID: 27374274
[TBL] [Abstract][Full Text] [Related]
4. Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis.
Lambova S; Müller-Ladner U
Nat Rev Rheumatol; 2011 Jan; 7(1):5-6. PubMed ID: 21119606
[No Abstract] [Full Text] [Related]
5. Bosentan for digital ulcers prevention does not worsen cardiopulmonary exercise test parameters in SSc patients with interstitial lung disease.
Romaniello A; Gigante A; Di Paolo M; Tallerini G; Barbano B; Amoroso D; Palange P; Rosato E
Int J Cardiol; 2016 Nov; 223():113-115. PubMed ID: 27537734
[No Abstract] [Full Text] [Related]
6. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
Humbert M; Cabane J
Rheumatology (Oxford); 2003 Jan; 42(1):191-3. PubMed ID: 12509640
[No Abstract] [Full Text] [Related]
7. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
Cozzi F; Pigatto E; Rizzo M; Favaro M; Zanatta E; Cardarelli S; Riato L; Punzi L
Clin Rheumatol; 2013 May; 32(5):679-83. PubMed ID: 23344686
[TBL] [Abstract][Full Text] [Related]
8. Resolution of severe digital ulceration during a course of Bosentan therapy.
Snyder MJ; Jacobs MR; Grau RG; Wilkes DS; Knox KS
Ann Intern Med; 2005 May; 142(9):802-3. PubMed ID: 15867420
[No Abstract] [Full Text] [Related]
9. Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
Agard C; Carpentier PH; Mouthon L; Clerson P; Gressin V; Bérezné A; Diot E; Jego P; Lok C; Sparsa A; Chatelus E; Van Kien AK; Quéré I; Sibilia J; Hachulla E
Scand J Rheumatol; 2014; 43(5):398-402. PubMed ID: 24720440
[TBL] [Abstract][Full Text] [Related]
10. Digital Ulcers, Systemic Sclerosis Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy.
Sharabi I; Tanay A; Zandman-Goddard G
Isr Med Assoc J; 2015 Feb; 17(2):126-7. PubMed ID: 26223094
[No Abstract] [Full Text] [Related]
11. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.
Ishikawa M; Endo Y; Yamazaki S; Sekiguchi A; Uchiyama A; Motegi SI
J Dermatol; 2023 Jun; 50(6):828-832. PubMed ID: 36651000
[TBL] [Abstract][Full Text] [Related]
13. [Digital ulcers in systemic sclerosis: use of endotheline antagonists].
Mota J; Castellano A; Santiago F; Carvalho P; Madeira AS; Pereira De Moura JM; Nascimento Costa JM
Acta Med Port; 2011; 24(5):837-42. PubMed ID: 22525638
[TBL] [Abstract][Full Text] [Related]
14. Bosentan for digital ulcers in patients with systemic sclerosis.
Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
[TBL] [Abstract][Full Text] [Related]
15. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.
Dhillon S
Drugs; 2009 Oct; 69(14):2005-24. PubMed ID: 19747014
[TBL] [Abstract][Full Text] [Related]
16. New hope for systemic sclerosis patients with digital ulcers.
Varga J
Curr Rheumatol Rep; 2005 Apr; 7(2):127-8. PubMed ID: 15760591
[No Abstract] [Full Text] [Related]
17. Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case.
Blaise S; Roustit M; Forli A; Imbert B; Cracowski JL
Int Wound J; 2017 Dec; 14(6):978-981. PubMed ID: 28303689
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)].
Riccardi MT; Chialà A; Lannone F; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2007; 59(2):135-9. PubMed ID: 17603693
[TBL] [Abstract][Full Text] [Related]
19. Digital ulcers: overt vascular disease in systemic sclerosis.
Steen V; Denton CP; Pope JE; Matucci-Cerinic M
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii19-24. PubMed ID: 19487218
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.
Moinzadeh P; Hunzelmann N; Krieg T
J Am Acad Dermatol; 2011 Sep; 65(3):e102-e104. PubMed ID: 21839301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
